Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

SHOCKING: Effector therapeutics s return on capital employed overview - What They Never Told You

According to Benzinga Pro, during Q4, eFFECTOR Therapeutics (NASDAQ:EFTR) earned $19.05 million, a 114.54% increase from the preceding quarter. eFFECTOR Therapeutics's sales decreased to $311.00 thousand, a 27.17% change since Q3. In Q3, eFFECTOR Therapeutics brought in $427.00 thousand in sales but only earned $8.88 million.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.